Erythropoietin increases macrophage-mediated T cell suppression

Area of Science:

• Immunology
• Cancer Biology
• Pharmacology

Background:

• Erythropoietin (EPO) treats anemia in cancer patients but may accelerate tumor progression.
• Tumor cells expressing EPO receptors (EPOR) were initially suspected as the mechanism.
• Tumor microenvironments (TMEs) have a high macrophage to lymphocyte ratio.

Purpose of the Study:

• To investigate EPO's effect on T cell suppression in a model mimicking the TME.
• To identify the cellular target of EPO's immunosuppressive effects in this model.

Main Methods:

• Cultured peritoneal cavity (PerC) cells with a high macrophage to T cell ratio.
• Stimulated T cells via T cell receptor (TCR) ligation.
• Assessed T cell proliferation and nitric oxide synthase (iNOS) expression.
• Administered EPO and tested iNOS inhibition (enzyme, genetic, or IFNγ signaling blockade).
• Used flow cytometry to detect EPOR expression.

Main Results:

• T cell proliferation was suppressed in PerC cultures, mediated by IFNγ-triggered iNOS.
• EPO treatment significantly increased T cell suppression.
• Inhibiting iNOS or blocking IFNγ signaling abrogated EPO's suppressive effect.
• EPOR was detected on macrophages (CD11b(+)F4/80(+)), not T cells.

Conclusions:

• EPO enhances T cell suppression in a TME-like model.
• This effect is mediated by EPO acting on macrophages, leading to iNOS induction.
• EPO may promote tumor progression by suppressing T cell responses via macrophages in the TME.